Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 117Cyclophosphamide 104fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Cytarabine 47Etoposide 44Mycophenolic Acid 41Filgrastim 40Whole-Body Irradiation 37Tacrolimus 36Melphalan 35Bortezomib 34Methotrexate 33Cyclosporine 33Busulfan 31Radiotherapy 30Vincristine 28Doxorubicin 27Dexamethasone 27Carmustine 25Antilymphocyte Serum 25Lenalidomide 23Bendamustine Hydrochloride 23ibrutinib 22Granulocyte Colony-Stimulating Factor 20obinutuzumab 18fludarabine 18acalabrutinib 18Prednisone 18venetoclax 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Mantle-Cell × Automobiles × Clear all
NCT05281809 2025-01-13

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04718883 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡